MikroScore
Science-backed ingredient evidence
Moderate Evidence Safety: Safe Study dose: 3000 mg/day

Beta-Glucan

Also known as: Beta-Glucan, Hafer-Beta-Glucan, Pilz-Beta-Glucane

Summary Moderate Evidence

Beta-glucans vary by source: oat forms are solid for cholesterol; fungal forms for immunity have weaker human evidence.

EU Health Claims: Approved

Oat and barley beta-glucans have specific EFSA-approved claims for cholesterol reduction under defined dosing. Broad immune claims lack comparable approval.

AI Summary

Quick verdict

Beta-glucans vary by source: oat forms are solid for cholesterol; fungal forms for immunity have weaker human evidence.

What the evidence supports

Oat and barley beta-glucans are well-studied for LDL-lowering. Fungal and yeast-derived beta-glucans have immune plausibility and some data but notably fewer robust clinical trials.

What is NOT supported

Long-term safety and rare adverse effects in humans remain insufficiently studied.

EU/EFSA status

Approved. Oat and barley beta-glucans have specific EFSA-approved claims for cholesterol reduction under de…

Safety

Safe

This AI summary is generated from the structured data on this page.

What are beta-glucans?

Beta-glucans are polysaccharides (long-chain carbohydrates) found in many foods and organisms. They differ structurally depending on source: oats and barley contain β-1,3/1,4-linked glucans; fungi, yeast, and certain mushrooms contain β-1,3/1,6-linked glucans. This structural difference matters fundamentally—different sources have different biological effects.

Source matters: Three main types

1. Oat and Barley Beta-Glucans (Soluble Fiber)

  • Structure: Predominantly β-1,3- and β-1,4-glycosidic linkages.
  • Primary effect: Cholesterol reduction via binding of cholesterol and bile acids in the GI tract, increasing fecal loss.
  • EFSA status: Approved health claim—oat/barley beta-glucan at ≥3 g/day is recognized for LDL-cholesterol lowering.

2. Fungal/Mushroom Beta-Glucans (β-1,3/1,6-linked)

  • Structure: Branched β-1,3 backbone with β-1,6 branches.
  • Proposed mechanisms: Immune cell (macrophage, NK cell) activation; TLR-2/TLR-6 signaling.
  • EFSA status: No approved health claims; immune effects remain unproven in humans.

3. Yeast Beta-Glucans

  • Similar to fungal forms; marketed for immunity.
  • Clinical evidence: Minimal; a few small studies in cold/infection rates show inconsistent results.

The evidence by source

Oat beta-glucan: Strong evidence for cholesterol

  • Meta-analyses and RCTs consistently show LDL reductions of 5–10% at doses of 3–5 g/day of high-molecular-weight oat beta-glucan.
  • This is EFSA-approved and forms the basis of authorized health claims on oat products.
  • Mechanism: Viscous fiber inhibits cholesterol absorption and increases bile acid excretion.
  • Effects are dose-dependent; less evidence below 3 g/day.

Fungal/mushroom beta-glucans: Weak human evidence for immunity

  • Immune markers: A handful of small studies (n < 50 each) report improvements in NK cell activity, phagocytosis, or inflammatory markers.
  • Clinical outcomes: Rare RCTs examining infection rates, illness duration, or symptom severity. Those that exist show mixed results.
  • Publication bias: Positive studies may be overrepresented; industry funding is common.
  • Bottom line: Plausible mechanism, but minimal clinical proof in humans.

Yeast beta-glucans: Similar gap

  • A few small studies suggest reductions in upper respiratory infection incidence or severity in athletes or immunocompromised populations.
  • Sample sizes are small (n < 100); blinding and methodological rigor vary.
  • No large-scale replication; clinical significance unclear.

Mechanisms (preclinical and plausible)

For oat/barley: Soluble fiber, viscosity, bile acid sequestration.

For fungal/yeast: TLR-mediated immune activation, macrophage and NK cell stimulation, anti-inflammatory cytokine shifts (IL-10 increase). These are real in cells and animals but uncertain in humans.

Regulatory and health claim status

  • Oat/barley: EFSA-approved claim for cholesterol reduction at ≥3 g/day of high-molecular-weight beta-glucan.
  • Fungal/mushroom/yeast: No approved EFSA claims for immunity or general health. Marketing claims like “immune boost” or “infection prevention” are not evidence-based per EU standards.

Dosage in studies

  • Oat beta-glucan: 3–5 g/day for cholesterol effect; 4–12 weeks for maximal response.
  • Fungal beta-glucans: 250–1500 mg/day in immune studies; no consensus dose.

Safety

All forms are well-tolerated:

  • Mild GI effects (bloating, gas) common with high-dose soluble fiber, especially when introduced suddenly.
  • No toxicity reported.
  • Absorption and bioavailability of fungal/yeast forms are poorly characterized.

Bottom line

For cholesterol reduction: Oat or barley beta-glucan at ≥3 g/day is solid, evidence-backed, and EFSA-approved. If you want to lower LDL naturally, oat beta-glucan is a legitimate first step.

For immunity: Fungal and yeast beta-glucans are mechanistically plausible but clinically unproven. Marketing claims far outpace evidence. If you’re interested in immune support, prioritize proven interventions: sleep, stress management, exercise, vitamin D (if deficient), and vaccination. Fungal beta-glucans may be an experiment, but not a foundation.

Practical advice: If choosing a beta-glucan product, check the source. Oat-derived offers better evidence for a specific health outcome (cholesterol). Fungal forms are interesting but speculative for immunity.

Key Studies

Cereal beta-glucan and cardiovascular disease risk reduction in overweight and obese populations: a systematic review and meta-analysis of lipid, blood pressure, and anthropometric parameters

Zheng et al. (2026)

Meta-analysis: Oat beta-glucan was consistently associated with lower LDL-cholesterol levels."

PubMed PMID 41362998

Sustainable production and pharmaceutical applications of β-glucan from microbial sources

Murphy et al. (2023)

Immunological mechanisms are plausible, but clinical evidence is weaker than many marketing claims suggest."

PubMed PMID 37301079

Dietary Supplements Containing Oat Beta-Glucan and/or Green Coffee (Poly)phenols Showed Limited Effect in Modulating Cardiometabolic Risk Biomarkers in Overweight/Obese Patients without a Lifestyle Intervention

García-Cordero et al. (2023)

Strongest evidence is for LDL-cholesterol reduction, not general wellness claims."

PubMed PMID 37432380
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.